发现NLRP3基因新错义变异导致以听力损失为主要表现的非典型冷吡啉相关周期性综合征,对抗白细胞介素-1治疗有反应
本研究在一个表现为常染色体显性遗传性进行性/急性感音神经性听力损失的家系中,发现NLRP3基因新错义变异(NM_001079821.3:c.1784G>A p.Ser595Asn)。对10例杂合个体和5名健康家庭成员进行离体功能评估,显示杂合个体炎症小体过度活化,支持该变异为致病性功能获得性变异。白细胞介素-1受体拮抗剂治疗使儿科患者听力损害在1至3个月内接近恢复。
要点
- NLRP3基因新错义变异c.1784G>A p.Ser595Asn在杂合个体中显示炎症小体过度活化。
- 白细胞介素-1受体拮抗剂治疗使儿科患者听力损害在1至3个月内接近恢复。
- 作者建议听力评估应包含高频和超高频范围,以早期发现亚临床感音神经性听力损失。
核心结论
- 早期诊断和抗白细胞介素-1治疗对逆转耳蜗损伤具有关键作用。
- 作者建议听力评估应包含高频和超高频范围,以早期发现亚临床感音神经性听力损失。
- 作者认为将炎症小体功能评估纳入临床评价可在诊断不明确的病例中帮助确立诊断。
研究设计与样本
- 对10例杂合个体和5名健康家庭成员进行离体NLRP3炎症小体功能评估。
主要发现
- 离体功能评估显示杂合个体中存在炎症小体过度活化,支持该错义变异为致病性功能获得性变异。
- 白细胞介素-1受体拮抗剂治疗后,儿科患者听力损害在1至3个月内接近恢复。
临床怎么用
- 作者建议听力评估应包含高频和超高频范围,以早期发现亚临床感音神经性听力损失。
- 作者认为将炎症小体功能评估纳入临床评价可在诊断不明确的病例中帮助确立诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cryopyrin-associated periodic syndromes (CAPS), also known as NLRP3-associated autoinflammatory diseases, are a spectrum of rare autoinflammatory diseases caused by gain-of-function variants in the NLRP3 gene, resulting in inflammasome hyperactivation and dysregulated release of interleukin-1β (IL-1β). Many patients with CAPS develop progressive sensorineural hearing loss (SNHL) because of cochlear autoinflammation, which may be the sole manifestation in rare cases. This study was undertaken to establish the suspected diagnosis of CAPS in a family presenting with autosomal-dominant progressive/acute SNHL and a novel missense variant in the NLRP3 gene of unknown significance (NM_001079821.3:c.1784G>A p.Ser595Asn). METHODS: We conducted an ex vivo functional assessment of the NLRP3 inflammasome in heterozygous individuals (n = 10) and healthy family members (n = 5). RESULTS: The assay revealed hyperactivation of the inflammasome among heterozygous individuals, supporting the hypothesis that this missense variant is a pathogenic gain-of-function variant. Administration of IL-1 receptor antagonist resulted in a substantial clinical improvement among pediatric patients, who exhibited near resolution of hearing impairment within 1 to 3 months of treatment. CONCLUSION: Our findings highlight the crucial role of early diagnosis and treatment with an anti-IL-1 agent in reversing cochlear damage. Furthermore, our results suggest that high- and ultrahigh-frequency ranges need to be included in the auditory assessment to enable early detection of subclinical SNHL. Finally, incorporating functional inflammasome assessment as part of the clinical evaluation could establish the diagnosis in inconclusive cases.
引用
- Birk-Bachar M, Cohen H, Sofrin-Drucker E, et al. Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes With Hearing Loss as the Primary Presentation, Responsive to Anti-Interleukin-1 Therapy. Arthritis Rheumatol. 2024. PMID: 37738164. doi:10.1002/art.42721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。